Iron Polymaltose

Registered South African indications:

• Iron deficiency anaemia

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• First trimester of pregnancy
• Anaemia not caused by iron deficiency
• Disturbances in iron utilisation
• Osler-Rendu-Weber syndrome
• Chronic polyarthritis
• Asthma
• Infectious renal complaints in the acute phase
• Uncontrolled hyperparathyroidism
• Decompensated hepatic cirrhosis
• Infectious hepatitis

Cautions

• Second and third trimester of pregnancy
• Renal impairment
• Hepatic impairment
• Atopic patients
• Cardiomyopathy
• Folic acid deficiency
• Acute or chronic infections

Forms avail. in SA and covered in this monograph: inj

Iron deficiency anaemia in patients unable to absorb or tolerate adequate amounts of iron taken orally

• IM: Initial: Test dose (see below); Maintenance: >45kg: 200mg (2 ampoules), dly; <45kg: 100mg (1 ampoule), dly; Continue daily dosing until total number of calculated ampoules given

Before administration of 1st dose of iron polymaltose in a new patient, an IM test dose of 25-50 mg should be given; if no adverse reaction occurs within a waiting period of at least 30 min, the remaining portion of dose can be given

Inject only into upper outer quadrant of the buttock; use a deep Z-track injection technique to avoid subcutaneous seepage

Paed. forms avail. in SA and covered in this monograph: inj

Iron deficiency anaemia in patients unable to absorb or tolerate adequate amounts of iron taken orally

• IM: Initial: Test dose (see below); Maintenance: <5kg: 25mg (1/4 ampoule), dly; 5-10kg: 50mg (1/2 ampoule), dly; 10-45kg: 100mg (1 ampoule), dly; Continue daily dosing until total number of calculated ampules given

Before administration of 1st dose of iron polymaltose in a new patient, an IM test dose of 12.5-25mg should be given; if no adverse reaction occurs within a waiting period of at least 30 min, the remaining portion of dose can be given

Inject only into upper outer quadrant of the buttock; use a deep Z-track injection technique to avoid subcutaneous seepage

Pregnancy

• Not rated (no information)

Breastfeeding

• Compatible
• Small quantities of unmodified iron polymaltose can pass into the breast milk.  Administration of this product in breastfeeding women is unlikely to cause adverse reactions on the suckling child  

Renal Impairment

• Caution; no dose adjustment recommended

Hepatic Impairment

• Caution; no dose adjustment recommended 

Elderly

• No dose adjustment recommended 

Porphyria  Information

• Not yet classified (NC)

Drugs in Sport

• Permitted - No warning

Central Nervous System Disorders

• Dizziness
• Headache

Cardiovascular Disorders

• Tachycardia

Gastrointestinal Disorders

• Abdominal disorders
• Nausea and vomiting

Musculoskeletal Disorders

• Arthralgia

Skin and Subcutaneous Tissue Disorders

• Injection site pain
• Skin discolouration

Immune, Blood and Lymphatic System Disorders

• Fever
• Leukocytosis
• Allergic/ anaphylactoid reactions
• Lymph node swelling

• Oral iron preparations
• Angiotensin-converting enzyme inhibitors

None routine

After absoprtion of the drug, iron is incorporated into haemoglobin, myoglobin, and iron-containing enzymes that are neccessary for oxidative processes in living tissues.

Injection (per 2ml) 100mg

• Ferrimed injection (Takeda) originator